BDBM528107 N-[(5-methoxy-2-methylphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US11180484, Example 41

SMILES COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C

InChI Key InChIKey=IYZKNUPIGJTMIO-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 528107   

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528107(N-[(5-methoxy-2-methylphenyl)methyl]-3-(methoxymet...)
Affinity DataIC50: 149nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528107(N-[(5-methoxy-2-methylphenyl)methyl]-3-(methoxymet...)
Affinity DataIC50: 4.00E+3nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528107(N-[(5-methoxy-2-methylphenyl)methyl]-3-(methoxymet...)
Affinity DataIC50: 4.00E+3nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528107(N-[(5-methoxy-2-methylphenyl)methyl]-3-(methoxymet...)
Affinity DataIC50: 4.00E+4nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent